Penumbra Reports Q2 2026 Results as Revenue Climbs 14.9% Year-Over-Year
The medical device maker's latest 10-Q filing reveals continued growth in thrombectomy systems, though international sales mix declined slightly from prior year.
Financial Performance
Penumbra, Inc. (PEN), the medical device company specializing in thrombectomy technologies, generated revenue of $390.0 million in the three months ended June 30, 2026, compared to $339.5 million in the year-ago period, according to its quarterly 10-Q filing submitted July 30, 2026. This represents a 14.9% increase year-over-year.
For the six-month period ended June 30, 2026, the company's international revenue represented 21.3% of total sales, down slightly from 22.0% in the comparable 2025 period (10-Q filing, 2026-07-30). The company noted that sales outside the United States are "denominated principally in the euro, with some sales being denominated in other currencies," creating foreign exchange exposure that remains unhedged.
Executive Certifications
CEO Adam Elsesser and CFO Maggie Yuen both signed standard Sarbanes-Oxley certifications accompanying the quarterly report. The executives certified that the report "does not contain any untrue statement of a material fact" and that the financial statements "fairly present in all material respects the financial condition, results of operations and cash flows of the registrant" (10-Q filing, 2026-07-30).
Both officers confirmed they have established and maintained disclosure controls and internal controls over financial reporting, evaluated their effectiveness, and disclosed any significant deficiencies to auditors and the audit committee.
Business Overview
Penumbra describes itself as "the world's leading thrombectomy company," focused on developing technologies for ischemic stroke, venous thromboembolism including pulmonary embolism, and acute limb ischemia (10-Q filing, 2026-07-30). The company's portfolio centers on computer-assisted vacuum thrombectomy (CAVT) for removing blood clots "from head-to-toe with speed, safety, and simplicity."
The Alameda, California-based company has been developing products since its 2004 founding, entering the thrombectomy market in 2007, access market in 2008, embolization market in 2011, and neurosurgical market in 2014. Its product families now include peripheral and neuro thrombectomy systems, peripheral and neuro embolization platforms, access delivery catheters, and neurosurgical evacuation devices.
Penumbra currently supports healthcare providers in more than 100 countries, though the company acknowledged that "when we introduce a next generation product or a new product designed to replace a current product, sales of the earlier generation product or the product replaced decline" (10-Q filing, 2026-07-30).
Upcoming Events and Insider Activity
According to MarginX data, Penumbra is expected to report Q3 2026 results on November 3, 2026. Recent insider activity includes a gift of 77,000 shares by CEO Adam Elsesser, a sale of 100 shares by Harpreet Grewal, and 150 shares withheld for taxes by Lambert Shiu.
The company's stock closed at $321.19 prior to the filing, valuing the medical device maker at approximately $13 billion in market capitalization.
This article was generated by MarginX from the 10-Q filing on 2026-07-30. It is not investment advice.